A phase 1 clinical trial, the results of which were published in the medical journal Lancet on Tuesday, has deemed the dissolvable microneedle flu patch to be “well tolerated” and safe for possible use.
Instead of receiving a flu vaccine with the typical prick of a syringe, the petite patch comes equipped with 100 microneedles that deliver a vaccine when pressed onto your arm.
“They’re really small; you can barely see them,” said Dr. Nadine Rouphael, an associate professor at the Emory University School of Medicine and lead author of the trial, which was a collaboration with the Georgia Institute of Technology.
She described the microneedles as minuscule enough to not cause as much pain as a traditional flu shot; however, collectively, they were associated with itchiness at the injection site in the trial.
“We also looked at the efficacy of the vaccine. Is it able to induce a similar immune response to the regular flu shot? And it did, actually,” Rouphael said.
The patch contains the same type of vaccine that would be found in a traditional needle and syringe, but it is placed within tiny needles in the patch instead of being placed in only one large one for a flu shot, she said.
“They are placed on a Band-Aid-like structure, and then that Band-Aid is applied, in this case, to the wrist,” she said. “There is an audible snap that you hear when you apply enough pressure to ensure that the microneedles will actually penetrate the skin. … After few minutes, we remove the patch. By then, those microneedles will be completely dissolved within the skin, along with the vaccine.”
‘They were impressed by how tiny it was’